Pasar al contenido principal

FUNCION DE LAS GLICOPROTEINAS DE LA SUPERFICIE CELULAR PODOPLANINA Y ENDOGLINA EN LA HOMEOSTASIS DE LA PIEL Y LA CARCINOGENESIS CUTANEA

SAF2013-46183-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2013
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Secretaría de Estado de Educación, Formación Profesional y Universidades
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo científico (JournalArticle)

Activation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancer.

  • Andradas, Clara
  • Blasco-Benito, Sandra
  • Castillo-Lluva, Sonia
  • Dillenburg-Pilla, Patricia
  • Diez-Alarcia, Rebeca
  • Juanes-García, Alba
  • García-Taboada, Elena
  • Hernando-Llorente, Rodrigo
  • Soriano, Joaquim
  • Hamann, Sigrid
  • Wenners, Antonia
  • Alkatout, Ibrahim
  • Klapper, Wolfram
  • Rocken, Christoph
  • Bauer, Maret
  • Arnold, Norbert
  • Quintanilla, Miguel
  • Megías, Diego
  • Vicente-Manzanares, Miguel
  • Urigüen, Leyre
  • Gutkind, J Silvio
  • Guzmán, Manuel
  • Pérez-Gómez, Eduardo
  • Sánchez, Cristina
The orphan G protein-coupled receptor GPR55 has been directly or indirectly related to basic alterations that drive malignant growth: uncontrolled cancer cell proliferation, sustained angiogenesis, and cancer cell adhesion and migration. However, little is known about the involvement of this receptor in metastasis. Here, we show that elevated GPR55 expression in human tumors is associated with the aggressive basal/triple-negative breast cancer population, higher probability to develop metastases, and therefore poor patient prognosis. Activation of GPR55 by its proposed endogenous ligand lysophosphatidylinositol confers pro-invasive features on breast cancer cells both in vitro and in vivo. Specifically, this effect is elicited by coupling to Gq/11 heterotrimeric proteins and the subsequent activation, through ERK, of the transcription factor ETV4/PEA3. Together, these data show that GPR55 promotes breast cancer metastasis, and supports the notion that this orphan receptor may constitute a new therapeutic target and potential biomarker in the highly aggressive triple-negative subtype.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Podoplanin mediates ECM degradation by squamous carcinoma cells through control of invadopodia stability

  • Martín-Villar, Ester
  • Borda-d'Agua, B.
  • Carrasco-Ramírez, Patricia
  • Renart, Jaime
  • Parsons, M.
  • Quintanilla, Miguel
  • Jones, Gareth E.
This work is licensed under a Creative Commons Attribution 4.0 International License., Invadopodia are actin-rich cell membrane projections used by invasive cells to penetrate the basement membrane. Control of invadopodia stability is critical for efficient degradation of the extracellular matrix (ECM); however, the underlying molecular mechanisms remain poorly understood. Here, we uncover a new role for podoplanin, a transmembrane glycoprotein closely associated with malignant progression of squamous cell carcinomas (SCCs), in the regulation of invadopodia-mediated matrix degradation. Podoplanin downregulation in SCC cells impairs invadopodia stability, thereby reducing the efficiency of ECM degradation. We report podoplanin as a novel component of invadopodia-associated adhesion rings, where it clusters prior to matrix degradation. Early podoplanin recruitment to invadopodia is dependent on lipid rafts, whereas ezrin/moesin proteins mediate podoplanin ring assembly. Finally, we demonstrate that podoplanin regulates invadopodia maturation by acting upstream of the ROCK-LIMK-Cofilin pathway through the control of RhoC GTPase activity. Thus, podoplanin has a key role in the regulation of invadopodia function in SCC cells, controlling the initial steps of cancer cell invasion., This work has been funded by grants from Cancer Research UK (C7125/A9926; A13651) to GEJ and EM-V, the Medical Research Council (G0401026) to GEJ and from the Spanish Ministry of Economy and Competitiveness (SAF 2010-19152/SAF2013-46183R) and Community of Madrid (S2010/BMD-2359, SkinModel-CM) to MQ. EM-V is currently a recipient of a Postdoctoral Research Contract from Fundación Científica Asociación Española Contra el Cáncer (AECC)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

New insights into the role of podoplanin in epithelial–mesenchymal transition

  • Renart, Jaime
  • Carrasco-Ramírez, Patricia
  • Fernández-Muñoz, Beatriz
  • Martín-Villar, Ester
  • Montero, Lucía
  • Yurrita, María M.
  • Quintanilla, Miguel
Podoplanin is a small mucin-like transmembrane protein expressed in several adult tissues and with an important role during embryogenesis. It is needed for the proper development of kidneys and lungs as well as accurate formation of the lymphatic vascular system. In addition, it is involved in the physiology of the immune system. A wide variety of tumors express podoplanin, both in the malignant cells and in the stroma. Although there are exceptions, the presence of podoplanin results in poor prognosis. The main consequence of forced podoplanin expression in established and tumor-derived cell lines is an increase in cell migration and, eventually, the triggering of an epithelial–mesenchymal transition, whereby cells acquire a fibroblastoid phenotype and increased motility. We will examine the current status of the role of podoplanin in the induction of epithelial–mesenchymal transition as well as the different interactions that lead to this program., Work in our laboratory is financed by grants SAF2013-46183-R from the Ministery of Economy and Competitiveness (MINECO), and S2010/BMD-2359 from the Comunidad Autónoma de Madrid. PC-R holds a predoctoral contract from the Ministery of Economy and Competitiveness. EM-V is the recipient of a postdoctoral research contract from the Scientific Foundation of Asociación Española Contra el Cáncer (AECC). MMY was supported by a contract from the Ministery of Economy and Competitiveness., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Enhanced tumorigenicity by mitochondrial DNA mild mutations

  • Cruz-Bermúdez, Alberto
  • Vallejo, Carmen G.
  • Vicente-Blanco, Ramiro J.
  • Gallardo, M. Esther
  • Fernández-Moreno, Miguel Ángel
  • Quintanilla, Miguel
  • Garesse, Rafael
To understand how mitochondria are involved in malignant transformation we have generated a collection of transmitochondrial cybrid cell lines on the same nuclear background (143B) but with mutant mitochondrial DNA (mtDNA) variants with different degrees of pathogenicity. These include the severe mutation in the tRNALys gene, m.8363G>A, and the three milder yet prevalent Leber's hereditary optic neuropathy (LHON) mutations in the MT-ND1 (m.3460G>A), MT-ND4 (m.11778G>A) and MT-ND6 (m.14484T>C) mitochondrial genes. We found that 143B ρ0 cells devoid of mtDNA and cybrids harboring wild type mtDNA or that causing severe mitochondrial dysfunction do not produce tumors when injected in nude mice. By contrast cybrids containing mild mutant mtDNAs exhibit different tumorigenic capacities, depending on OXPHOS dysfunction. The differences in tumorigenicity correlate with an enhanced resistance to apoptosis and high levels of NOX expression. However, the final capacity of the different cybrid cell lines to generate tumors is most likely a consequence of a complex array of pro-oncogenic and anti-oncogenic factors associated with mitochondrial dysfunction. Our results demonstrate the essential role of mtDNA in tumorigenesis and explain the numerous and varied mtDNA mutations found in human tumors, most of which give rise to mild mitochondrial dysfunction., This work was supported by the “Instituto de Salud Carlos III” [PI 10/0703 and PI13/00556 to R.G and PI 04/1001 to MAFM]; “Comunidad Autónoma de Madrid” [S2010/BMD-2402 to R.G and S2010/BMD-2359 to MQ); “Fundación Mutua Madrileña” [10.04.02.0064 to MAFM] and the Spanish Ministry of Economy and Competitiveness (grant SAF2013-46183-R to MQ). M.E.G. is a staff scientist at the Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Spain., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Podoplanin is a component of extracellular vesicles that reprograms cell-derived exosomal proteins and modulates lymphatic vessel formation

  • Carrasco-Ramírez, Patricia
  • Andrés, Germán
  • Martín-Villar, Ester
  • Renart, Jaime
  • Quintanilla, Miguel
This is an open-access article distributed under the terms of the Creative Commons Attribution License.-- et al., Podoplanin (PDPN) is a transmembrane glycoprotein that plays crucial roles in embryonic development, the immune response, and malignant progression. Here, we report that cells ectopically or endogenously expressing PDPN release extracellular vesicles (EVs) that contain PDPN mRNA and protein. PDPN incorporates into membrane shed microvesicles (MVs) and endosomal-derived exosomes (EXOs), where it was found to colocalize with the canonical EV marker CD63 by immunoelectron microscopy. We have previously found that expression of PDPN in MDCK cells induces an epithelial-mesenchymal transition (EMT). Proteomic profiling of MDCK-PDPN cells compared to control cells shows that PDPN-induced EMT is associated with upregulation of oncogenic proteins and diminished expression of tumor suppressors. Proteomic analysis of exosomes reveals that MDCK-PDPN EXOs were enriched in protein cargos involved in cell adhesion, cytoskeletal remodeling, signal transduction and, importantly, intracellular trafficking and EV biogenesis. Indeed, expression of PDPN in MDCK cells stimulated both EXO and MV production, while knockdown of endogenous PDPN in human HN5 squamous carcinoma cells reduced EXO production and inhibited tumorigenesis. EXOs released from MDCK-PDPN and control cells both stimulated in vitro angiogenesis, but only EXOs containing PDPN were shown to promote lymphatic vessel formation. This effect was mediated by PDPN on the surface of EXOs, as demonstrated by a neutralizing specific monoclonal antibody. These results contribute to our understanding of PDPN-induced EMT in association to tumor progression, and suggest an important role for PDPN in EV biogenesis and/or release and for PDPN-EXOs in modulating lymphangiogenesis., This work was supported by grants SAF2013-46183-R from the Spanish Ministry of Economy and Competitiveness and S2010/BMD-2359 (SkinModel) from the Community of Madrid (to MQ). Further support from the National Health and Medical Research Council of Australia Program, grant 487922 and project grant 1057741 (to RJS). PC-R is funded by the Spanish FPI (Formación de Personal Investigador) program. SKG is supported by La Trobe University Postgraduate Scholarship, Australia. EM-V is the recipient of a postdoctoral research contract from the scientific foundation of AECC (Asociación Española Contra el Cáncer)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Antithrombin controls tumor migration, invasion and angiogenesis by inhibition of enteropeptidase

  • Luengo-Gil, Ginés
  • Calvo, María I.
  • Martín-Villar, Ester
  • Quintanilla, Miguel
  • Martínez-Martínez, Irene
This work is licensed under a Creative Commons Attribution 4.0 International License.-- et al., Antithrombin is a key inhibitor of the coagulation cascade, but it may also function as an anti-inflammatory, anti-angiogenic, anti-viral and anti-apoptotic protein. Here, we report a novel function of antithrombin as a modulator of tumor cell migration and invasion. Antithrombin inhibited enteropeptidase on the membrane surface of HT-29, A549 and U-87 MG cells. The inhibitory process required the activation of antithrombin by heparin, and the reactive center loop and the heparin binding domain were essential. Surprisingly, antithrombin non-covalently inhibited enteropeptidase, revealing a novel mechanism of inhibition for this serpin. Moreover, as a consequence of this inhibition, antithrombin was cleaved, resulting in a molecule with anti-angiogenic properties that reduced vessel-like formation of endothelial cells. The addition of antithrombin and heparin to U-87 MG and A549 cells reduced motility in wound healing assays, inhibited the invasion in transwell assays and the degradation of a gelatin matrix mediated by invadopodia. These processes were controlled by enteropeptidase, as demonstrated by RNA interference experiments. Carcinoma cell xenografts in nude mice showed in vivo co-localization of enteropeptidase and antithrombin. Finally, treatment with heparin reduced experimental metastasis induced by HT29 cells in vivo. In conclusion, the inhibition of enteropeptidase by antithrombin may have a double anti-tumor effect through inhibiting a protease involved in metastasis and generating an anti-angiogenic molecule., This work was supported by CP13/00126 (ISCIII & FEDER), PI15/00079 (ISCIII), SAF2013-46183-R from the Spanish Ministry of Economy and Competitiveness) and the Programa de Movilidad Jiménez de la Espada from Seneca Foundation (Murcia). G. Luengo-Gil holds a grant from the Spanish Society of Thrombosis and Haemostasis (SETH), S. Águila holds an FPI grant from the Ministerio de Ciencia e Innovación, and I. Martínez-Martínez has a Miguel Servet contract from ISCIII. M.I. Calvo holds a postdoctoral contract associated to the project RTC-2014-2626-1, and E. Martín-Villar is the recipient of a postdoctoral research contract from the scientific foundation of Asociación Española Contra el Cáncer (AECC)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Activation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancer

  • Andradas, Clara
  • Quintanilla, Miguel
  • Megías, Diego
  • Pérez-Gómez, Eduardo
  • Sánchez, Cristina
et al., The orphan G protein-coupled receptor GPR55 has been directly or indirectly related to basic alterations that drive malignant growth: uncontrolled cancer cell proliferation, sustained angiogenesis, and cancer cell adhesion and migration. However, little is known about the involvement of this receptor in metastasis. Here, we show that elevated GPR55 expression in human tumors is associated with the aggressive basal/triple-negative breast cancer population, higher probability to develop metastases, and therefore poor patient prognosis. Activation of GPR55 by its proposed endogenous ligand lysophosphatidylinositol confers pro-invasive features on breast cancer cells both in vitro and in vivo. Specifically, this effect is elicited by coupling to G heterotrimeric proteins and the subsequent activation, through ERK, of the transcription factor ETV4/PEA3. Together, these data show that GPR55 promotes breast cancer metastasis, and supports the notion that this orphan receptor may constitute a new therapeutic target and potential biomarker in the highly aggressive triple-negative subtype., This work was supported by grants from Spanish Ministry of Economy and Competitiveness [PI11/00295 to CS, PI14/01101 to CS and EP-G, SAF2013-46183-R to MQ, and SAF2014-54705-R to MV-M, supported with European Regional Development (FEDER) funds] and Madrid Regional Government (S2010/BMD-2308 to MG, and 2010/ BMD-2359 to MQ). EPG was a recipient of a Postdoctoral Research Contract from Fundación Científica Asociación Española Contra el Cáncer and a Federation of the Societies of Biochemistry and Molecular Biology (FEBS) Short-term Fellowship. SB-B and SC-L are recipients of a Formación de Profesorado Universitario (FPU) fellowship and a Ramón y Cajal research contract, respectively, from the Spanish Ministry of Economy and Competitiveness., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Reduced expression of the murine HLA-G homolog Qa-2 is associated with malignancy, epithelial-mesenchymal transition and stemness in breast cancer cells

  • Luciene da Silva, Istéfani
  • Montero, Lucía
  • Martín-Villar, Ester
  • Martín-Pérez, Jorge
  • Sainz, Bruno Jr.
  • Renart, Jaime
  • Toscano Simões, Renata
  • Soares Veloso, Emerson
  • Salviano Teixeira, Cláudia
  • Oliveira, Mônica C. de
  • Ferreira, Enio
  • Quintanilla, Miguel
Qa-2 is believed to mediate a protective immune response against cancer; however, little is known about the role of Qa-2 in tumorigenesis. Here, we used 4T1 breast cancer cells to study the involvement of Qa-2 in tumor progression in a syngeneic host. Qa-2 expression was reduced during in vivo tumor growth and in cell lines derived from 4T1-induced tumors. Tumor-derived cells elicited an epithelial-mesenchymal transition associated with upregulation of Zeb1 and Twist1/2 and enhanced tumor initiating and invasive capacities. Furthermore, these cells showed increased stem characteristics, as demonstrated by upregulation of Hes1, Sox2 and Oct3/4, and enrichment of CD44high/CD24median/low cells. Remarkably, Qa-2 cell-surface expression was excluded from the CD44high/CD24median/low subpopulation. Tumor-derived cells showed increased Src activity, and treatment of these cells with the Src kinase inhibitor PP2 enhanced Qa-2 but reduced Sox2 and CD44high/CD24median/low expression levels, suggesting that Src signaling, while positively associated with stemness, negatively regulates Qa-2 expression in breast cancer. Finally, overexpression of the Qa-2 family member Q7 on the cell surface slowed down in vivo tumor growth and reduced the metastatic potential of 4T1 cells. These results suggest an anti-malignant role for Qa-2 in breast cancer development, which appears to be absent from cancer stem cells., Tis work was supported by grants: APQ-04269-10 and RED-00011-14 from the Foundation for Research Support of the State of Minas Gerais (FAPEMIG), to EF; SAF2012-38048 and SAF2013-46183-R from the Spanish Ministry of Economy and Competitiveness/European Funding for Regional Development (MINECO/FEDER), to JM-P and MQ, respectively. ILDS was the recipient of an international fellowship from the CAPES Foundation (Higher Level Personnel Improvement Commission), Ministry of Education of Brazil, procs. Nr. 999999.009972/2014-05. LM-M was funded by the Spanish FPI program (BES-2014-069327)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Evolutionary history of the podoplanin gene

  • Renart, Jaime
  • San Mauro, Diego
  • Agorreta, Ainhoa
  • Rutherford, Kim
  • Gemmell, Neil J.
  • Quintanilla, Miguel
Podoplanin is a type I small mucin-like protein involved in cell motility. We have identified and studied the podoplanin coding sequence in 201 species of vertebrates, ranging from cartilaginous fishes to mammals. The N-terminal signal peptide is coded by the first exon; the transmembrane and intracellular domains are coded by the third exon (except for the last amino acid, coded in another exon with a long 3'-UTR). The extracellular domain has undergone variation during evolutionary time, having a single exon in cartilaginous fishes, teleosts, coelacanths and lungfishes. In amphibians, this single exon has been split in two, and in amniotes, another exon has been acquired, although it has been secondarily lost in Squamata. The podoplanin evolutionary tree agrees with the species tree in most cases. Two functional elements in the proteins, the GXXXG dimerization motif in the transmembrane domain and the region where podoplanin is cleaved by γ-secretase are subjected to positive selection., JR and MQ were supported by grant SAF2013-46183-R from the Ministerio de Economía y Competitividad, Spain. AA and DSM were financed by grant CGL2012-40082, and DSM also supported by grant RYC-2011-09321, both from the Ministerio de Economía y Competitividad, Spain., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A role for the Tgf-β/Bmp co-receptor Endoglin in the molecular oscillator that regulates the hair follicle cycle

  • Calvo, María I.
  • Fernández-Martos, Sandra
  • Carrasco, Elisa
  • Moreno-Bueno, Gema
  • Bernabéu, Carmelo
  • Quintanilla, Miguel
  • Espada, Jesús
The hair follicle is a biological oscillator that alternates growth, regression, and rest phases driven by the sequential activation of the proliferation/differentiation programs of resident stem cell populations. The activation of hair follicle stem cell niches and subsequent entry into the growing phase is mainly regulated by Wnt/β-catenin signalling, while regression and resting phases are mainly regulated by Tgf-β/Bmp/Smad activity. A major question still unresolved is the nature of the molecular switch that dictates the coordinated transition between both signalling pathways. Here we have focused on the role of Endoglin (Eng), a key co-receptor for members of the Tgf-β/Bmp family of growth factors. Using an Eng haploinsufficient mouse model, we report that Eng is required to maintain a correct follicle cycling pattern and for an adequate stimulation of hair follicle stem cell niches. We further report that β-catenin binds to the Eng promoter depending on Bmp signalling. Moreover, we show that β-catenin interacts with Smad4 in a Bmp/Eng-dependent context and both proteins act synergistically to activate Eng promoter transcription. These observations point to the existence of a growth/rest switching mechanism in the hair follicle that is based on an Eng-dependent feedback cross-talk between Wnt/β-catenin and Bmp/Smad signals., This work was supported by grants from Ministerio de Economía y Competitividad of Spain (RTC-2014-2626-1 to J.E., SAF2013-46183-R to M.Q., and SAF2013-43421-R to C.B.), Comunidad de Madrid (S2010/BMD-2359, SkinModel to J.E. and M.Q.), Instituto de Salud Carlos III (PI15/01458 to J.E.), and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER; ISCIII-CB06/07/0038 to C.B.) financed jointly by the European Regional Development Funds (FEDER). E.C. and M.I.C. were supported by Spanish MECD-FPU and UAM-FPI fellowships, respectively., Peer reviewed